DSC Advisors’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$1.31M Hold
13,929
11.93% 3
2024
Q2
$1.37M Hold
13,929
4.58% 5
2024
Q1
$2.14M Hold
13,929
3.42% 7
2023
Q4
$1.62M Buy
13,929
+11,629
+506% +$1.81M 2.68% 7
2023
Q3
$460K Hold
2,300
0.59% 15
2023
Q2
$467K Hold
2,300
0.7% 11
2023
Q1
$354K Buy
2,300
+556
+32% +$99.8K 0.31% 12
2022
Q4
$236K Sell
1,744
-1,223
-41% -$244K 0.54% 12
2022
Q3
$596K Hold
2,967
0.61% 28
2022
Q2
$1.04M Hold
2,967
1.04% 17
2022
Q1
$1.74M Buy
2,967
+133
+5% +$79K 0.6% 17
2021
Q4
$2.6M Buy
2,834
+1,612
+132% +$1.73M 2.01% 10
2021
Q3
$1.53M Hold
1,222
1.55% 14
2021
Q2
$3.86M Buy
1,222
+69
+6% +$273K 2.79% 12
2021
Q1
$7.11M Hold
1,153
4.4% 7
2020
Q4
$6.56M Hold
1,153
5.42% 7
2020
Q3
$6.89M Sell
1,153
-58
-5% -$338K 4.61% 7
2020
Q2
$7.54M Buy
1,211
+634
+110% +$4.29M 8.27% 6
2020
Q1
$5.56M Buy
+577
New +$9.05M 5.43% 8

Other funds holding YARW

DSC Advisors's YARW Position: Q3 2024 in Review

DSC Advisors held its Yarrow Bioscience, Inc. Common Stock (YARW) position steady in Q3 2024 at 13,929 shares worth $1.31M. The position accounts for 11.93% of the portfolio, ranked #3.

DSC Advisors first reported a position in YARW in Q1 2020 and has held it in 19 quarters since. The position peaked at $7.54M in Q2 2020. 32 funds tracked by Wall St. Rank hold YARW as of Q3 2024.

  • DSC Advisors held 13,929 shares of Yarrow Bioscience, Inc. Common Stock worth $1.31M as of Q3 2024.
  • DSC Advisors left its Yarrow Bioscience, Inc. Common Stock share count unchanged in Q3 2024.
  • Yarrow Bioscience, Inc. Common Stock made up 11.93% of DSC Advisors's portfolio in Q3 2024, its #3 holding.
  • DSC Advisors first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2020 and has held it in 19 quarters since.
  • DSC Advisors's Yarrow Bioscience, Inc. Common Stock position peaked at $7.54M in Q2 2020.
  • 32 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q3 2024.

Based on DSC Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.